UK Markets close in 6 hrs 32 mins

GenSight Biologics S.A. (GSGTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.75000.0000 (0.00%)
At close: 10:32AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.7500
Open4.7500
BidN/A x N/A
AskN/A x N/A
Day's range4.7500 - 4.7500
52-week range4.5000 - 11.3000
Volume10,000
Avg. volume0
Market cap218.118M
Beta (5Y monthly)2.61
PE ratio (TTM)N/A
EPS (TTM)-0.7690
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    GenSight Biologics: Annual General Meeting on May 25, 2022

    PARIS, May 04, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that it will hold its Annual General Meeting on May 25, 2022, at 9:00 am CEST at the Company’s headquarters, 74 rue du Faubourg Saint-Antoine, 75012 Paris, France (*).

  • Business Wire

    GenSight Biologics Announces the Filing of its 2021 Universal Registration Document

    PARIS, April 29, 2022--Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced the filing of its 2021 Universal Registration Document (URD) in English with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference D.22-0390.

  • Business Wire

    GenSight Biologics Reports Cash Position and Revenues as of March 31, 2022

    PARIS, April 21, 2022--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position and revenues as of March 31, 2022.